Lexicon Pharmaceuticals announced new research showing sotagliflozin, a dual SGLT1/2 inhibitor, significantly reduces blood clot formation under arterial and venous conditions and directly lowers myocardial work in hypertrophic cardiomyopathy (HCM) heart tissue. These findings, presented at the 2026 American Heart Association Scientific Sessions, suggest sotagliflozin's potential benefits beyond kidney and metabolic effects, supporting its ongoing Phase 3 SONATA-HCM trial. Topline results from this trial are expected in Q1 2027, potentially offering a new treatment option for HCM patients.
Sotagliflozin's cardiovascular effects are highlighted alongside Pluang's Health-sector market data. For readers following health stocks, here is Pluang's market snapshot as of Nov 09, 2026 19:41 WIB: Out of 150 priced US health-sector stocks, 121 rose and 18 fell. Notable movers include CTXR at USD 0.54 with a -2.98% change and a typical hold time of 19 days, LQDA at USD 45.67 with a +2.86% change and a 4-day hold time, and HIMS at USD 25.29 with a -2.73% change and a 24-day hold time.
Neo Security, Inc. has launched Neoverse, a free AI software intelligence engine that researches and classifies over 4 million AI apps, extensions, and servers to assess their capabilities and security risks. Integrated into Neo's platform, Neoverse ...
AnorTech Inc. completed a $7.55 million share exchange with Nasdaq-listed Greenland Mines, increasing Greenland Mines' ownership in AnorTech to 19.9%. Greenland Mines acquired over 25 million AnorTech shares in exchange for Greenland Mines shares val...
Microsoft will retire the backend services for its UWP Map Control and Windows Maps APIs on November 30, 2026, ending map functionality in many Windows desktop and tablet applications. OnTerra Systems, a Microsoft partner, has developed an off-the-sh...
Marengo Therapeutics presented interim Phase 2 results from the STARt-002 trial combining invikafusp alfa, a selective T-cell agonist, with sacituzumab govitecan in metastatic triple-negative and HR-positive/HER2-negative breast cancer. The trial sho...
Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against The Ensign Group, Netcapital Inc., and Webull Corporation. These lawsuits allege misleading statements and failure to di...
